153 related articles for article (PubMed ID: 36960627)
1. Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non-Small Cell Lung Cancer.
Lee SH; Kim EY; Han JM; Han G; Chang YS
Cancer Res Treat; 2023 Jul; 55(3):851-864. PubMed ID: 36960627
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer.
Kim EY; Lee JG; Lee JM; Kim A; Yoo HC; Kim K; Lee M; Lee C; Han G; Han JM; Chang YS
Ther Adv Med Oncol; 2019; 11():1758835919846798. PubMed ID: 31205503
[TBL] [Abstract][Full Text] [Related]
3. Developing a comprehensive solution aimed to disrupt LARS1/RagD protein-protein interaction.
Raevsky A; Kovalenko O; Bulgakov E; Sharifi M; Volochnyuk D; Tukalo M
J Biomol Struct Dyn; 2024; 42(2):747-758. PubMed ID: 36995308
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
5. O-GlcNAc modification of leucyl-tRNA synthetase 1 integrates leucine and glucose availability to regulate mTORC1 and the metabolic fate of leucine.
Kim K; Yoo HC; Kim BG; Kim S; Sung Y; Yoon I; Yu YC; Park SJ; Kim JH; Myung K; Hwang KY; Kim S; Han JM
Nat Commun; 2022 May; 13(1):2904. PubMed ID: 35614056
[TBL] [Abstract][Full Text] [Related]
6. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
Ma Z; Zhu L; Luo X; Zhai S; Li P; Wang X
Cancer Biol Ther; 2012 Sep; 13(11):1009-17. PubMed ID: 22825337
[TBL] [Abstract][Full Text] [Related]
7. Leucine-sensing mechanism of leucyl-tRNA synthetase 1 for mTORC1 activation.
Kim S; Yoon I; Son J; Park J; Kim K; Lee JH; Park SY; Kang BS; Han JM; Hwang KY; Kim S
Cell Rep; 2021 Apr; 35(4):109031. PubMed ID: 33910001
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
9. MEK inhibitors under development for treatment of non-small-cell lung cancer.
Kim C; Giaccone G
Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
[TBL] [Abstract][Full Text] [Related]
10. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition.
Chen Y; Li WW; Peng P; Zhao WH; Tian YJ; Huang Y; Xia S; Chen Y
Acta Pharmacol Sin; 2019 Aug; 40(8):1085-1094. PubMed ID: 30796356
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Qu GP; Shi M; Wang D; Wu JH; Wang P; Gong ML; Zhang ZJ
BMC Pulm Med; 2021 Jul; 21(1):208. PubMed ID: 34210314
[TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
17. Leucyl-tRNA synthetase 1 is required for proliferation of TSC-null cells.
Bae JH; Kim JH
Biochem Biophys Res Commun; 2021 Sep; 571():159-166. PubMed ID: 34325132
[TBL] [Abstract][Full Text] [Related]
18. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
[TBL] [Abstract][Full Text] [Related]
19. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53.
Lee SO; Andey T; Jin UH; Kim K; Singh M; Safe S
Oncogene; 2012 Jul; 31(27):3265-76. PubMed ID: 22081070
[TBL] [Abstract][Full Text] [Related]
20. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
